Heterocyclic Building Blocks

Sulfur-Containing Heterocycles

Thienopyridine Derivatives Thiophene Derivatives

Indole Derivatives

Spiro cyclic Heterocycles

Bridged Bicyclic Heterocycles

Pidine Derivatives

Pyridine Derivatives

Isoquinoline Derivatives

Fused Bicyclic Heterocycles

Pyridine Derivatives

Pyrazole Derivatives

Sulfur-Containing Heterocycles

Thiophene Derivatives

Fused Bicyclic Heterocycles

Azepine Derivatives

Benzazepines

Pyridazine Derivatives

Fused Bicyclic Heterocycles

Pyrazolo-pyrimidine Derivatives Isoquinoline Derivatives Pyrrolopyrimidine Derivatives Pyrrolopyridine Derivatives Imidazopyridine Derivatives Pyrazolo-pyridine Derivatives

Sulfur-Containing Heterocycles

Spiro cyclic Heterocycles

Coumarin Derivatives

Pyrrole Derivatives

Benzoxaborole Derivatives

Pyridone Derivatives

Oncology Drug Intermediates

Enzyme Inhibitor Intermediates

Kinase Inhibitors

En Inhibitor Intermediates

Kinase Inhibitors

Alkylating Agents

Cytotoxic Natural Products

Neurological Intermediates

Anticonvulsants

Cardiovascular Intermediates

Cardiac Glycosides

Vasodilator Intermediates

Angiotensin II Receptor Blockers

Calcium Channel Blockers

Organic Synthesis Intermediates

Nitrile Intermediates

Heterocyclic Building Blocks

Quinoline Derivatives

Aromatic Alcohols

Halogenated Aromatic Alcohols Halogenated Aromatic Alcohols Halogenated Aromatic Alcohols Halogenated Aromatic Alcohols Halogenated Aromatic Alcohols Halogenated Aromatic Alcohols Halogenated Aromatic Alcohols Halogenated Aromatic Alcohols Halogenated Aromatic Alcohols Nitro Aromatic Alcohols Nitro Aromatic Alcohols Nitro Aromatic Alcohols Halogenated Aromatic Alcohols

Ketone Intermediates

Antidiabetic Intermediates

Antimalarial Intermediates

Amide Intermediates

Benzamide Derivatives

Enzyme Inhibitor Intermediates

Kinase Inhibitors

Carbonic Anhydrase Inhibitors

Nitro Aromatic Derivatives

Drug Discovery Reagents

Antimalarial Intermediates

Oncology Drug Intermediates

Enzyme Inhibitor Intermediates

Sulfonamide Intermediates

Neurological Research Reagents

Heterocyclic Building Blocks

Antihistamine Intermediates

Phenolic Intermediates

Halogenated Phenols

Aliphatic Carboxylic Acid Derivatives

Malonic Acid Derivatives

Drug Delivery Intermediates

Surface Modification Reagents

REAGENT

(R)-3-(5-Bromo-1H-indol-3-yl)-2-((tert-butoxycarbonyl)amino)propanoic acid

97%

CAS:114873-17-5

Formula:C₁₆H₁₉BrN₂O₄

MW:383.24 g/mol

฿7,140.00

View

REAGENT

(1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carboxylic acid

97%

CAS:171754-02-2

Formula:C₇H₁₁NO₂

MW:141.1673 g/mol

฿8,840.00

View

REAGENT

(R)-3-(tert-Butoxymethyl)piperazin-2-one

98%

CAS:1222102-49-9

Formula:C₉H₁₈N₂O₂

MW:186.25 g/mol

฿11,220.00

View

REAGENT

(R)-7-Chloro-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride

98%

CAS:1257526-91-2

Formula:C₁₀H₁₃Cl₂N

MW:218.12 g/mol

฿18,870.00

View

REAGENT

(R)-N-(5-((4-((5-Chloro-4-fluoro-2-(2-hydroxypropan-2-yl)phenyl)amino)pyrimidin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide

98%

CAS:2370013-12-8

Formula:C₂₉H₃₅ClFN₇O₃

MW:584.08 g/mol

฿5,880.00

View

REAGENT

(3aR,6aR)-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-one

97%

CAS:595581-64-9

Formula:C₈H₁₂O₃

MW:156.181 g/mol

฿5,340.00

View

REAGENT

Rel-(1R,2R)-2-(methylamino)cyclopentan-1-ol

97%

CAS:666697-60-5

Formula:C₆H₁₃NO

MW:115.173 g/mol

฿10,430.00

View

REAGENT

Rac-methyl (1R,2S,3R,4S)-3-aminobicyclo[2.2.1]heptane-2-carboxylate hydrochloride, exo

98%

CAS:1071520-51-8

Formula:C₉H₁₆ClNO₂

MW:205.68 g/mol

฿21,280.00

View

REAGENT

(1R,4R)-2-oxa-5-azabicyclo[2.2.2]octanehydrochloride

97%

CAS:2306254-89-5

Formula:C₆H₁₂ClNO

MW:149.62 g/mol

฿38,410.00

View

REAGENT

Rac-methyl(1R,3S)-3-amino-2,3-dihydro-1H-indene-1-carboxylatehydrochloride,cis

96%

CAS:111634-93-6

Formula:C₁₁H₁₄ClNO₂

MW:227.69 g/mol

฿26,230.00

View

Cart

No products

Subtotal: 0.00

Total 0.00 THB

Cart Checkout

Researcher Network Do you belong to Researcher Network? Use your organization email to unlock organization invoice requirements and eligibility. View details